ROCKLAND, Mass.--(BUSINESS WIRE)--EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced its participation in the Merck Global Grants initiative – a program that underscores the company’s commitment to funding scientific innovation via research grants and supporting medical education of healthcare providers and patients around the world. The initiative encompasses all of the various grants that EMD Serono offers, including its Grants for Innovation in Research, its Independent Medical Grants, and Grants for Medical Education of Healthcare Providers and Patients.
The global program totals an annual commitment of €20 million across all grants programs, highlighting the company’s collective efforts to promote advances in the field of medicine, address recognized gaps in healthcare knowledge, and improve the quality of patient care.
“EMD Serono has a long-standing reputation as a strong advocate for scientific innovation and medical education, believing that both are integral to helping healthcare professionals deliver high-quality, innovative healthcare to patients,” said Steven Hildemann, Global Chief Medical Officer and Head of Global Medical and Safety at the biopharmaceutical division of Merck KGaA, Darmstadt, Germany.
EMD Serono’s research grants program supports investigator-initiated clinical and pre-clinical research in various therapeutic areas. Its Innovation Grants focus on areas in which EMD Serono has a strong R&D presence, such as the Grant for Oncology Innovation, the Grant for Multiple Sclerosis Innovation, and the Grant for Fertility Innovation. For information about EMD Serono’s Innovation Grants, visit the following:
EMD Serono’s medical education grants program supports accredited educational activities for healthcare providers that improve patient care and provide valuable information to the medical community. The program also supports fellowships and patient education initiatives. All grants are processed through an online web portal which allows highly transparent interactions with applicants. For more information on EMD Serono’s medical education grants, please visit www.grants.emdserono.com.
For more information on independent medical grants available in the United States, please visit www.img-emdserono.com.
About EMD Serono, Inc.
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a specialized biopharmaceutical company dedicated to developing therapies with groundbreaking potential. The company has strong market positions in neurology, endocrinology and in reproductive health. In addition, EMD Serono has an enduring commitment to solve the unsolvable, with state-of-the-art science dedicated to developing new therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology. With a long-standing history of industry expertise and a dedication to shape the future of healthcare, the company’s US footprint continues to grow, with approximately 1,000 employees around the country and fully integrated commercial, clinical and research operations in the company’s home state of Massachusetts.
For more information, please visit www.emdserono.com.
About Merck KGaA, Darmstadt, Germany
Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. Its subsidiaries in Canada and the United States operate under the umbrella brand EMD. Around 38,000 employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. The company generated total revenues of €11.1 billion in 2013 with its four divisions: Biopharmaceuticals, Consumer Health, Performance Materials and Life Science Tools. Merck KGaA of Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the name has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day.